Intraperitoneal Chemotherapy
Hormonal Status May Contribute to Sex-Based Survival Differences in Epithelioid Peritoneal Mesothelioma
Annals of Surgical Oncology 2026 March 12 [Link] Kaelyn C Cummins, Olivia Sears, Elio R Bitar, Chengli Shen, Allan Tsung, Samantha M Ruff Abstract Background: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is central to treating patients with epithelioid peritoneal mesothelioma (EPM). Male sex is a negative prognostic factor in mesothelioma, but the reasons…
Read MoreNeoadjuvant Pressurized Intraperitoneal Aerosol Chemotherapy for Conversion to Cytoreductive Surgery in Unresectable Malignant Peritoneal Mesothelioma: A Report of 2 Cases
The American Journal of Case Reports 2026 February [Link] Arnaldo Urbano-Ruiz, Bruna Latronico Palma, Ronaldo Elias Carnut Rego, Daniel Bianqui Guaraldo da Silva, Bianca Fava, Erlan Araujo Falcão , Michelle Louise Rodrigues Barbosa da Silva, Julia Rodrigues Leandro Uliano Abstract BACKGROUND Peritoneal mesothelioma (PM) is the second most common presentation site of malignant mesothelioma. The…
Read MoreSafety of secondary CRS/HIPEC in peritoneal surface malignancies: Insights from a national cohort study
European Journal of Surgical Oncology 2026 January 17 [Link] Lukas Pollmann, Jürgen Zieren, Nicola S Pollmann, Urs Giger-Pabst, Pompiliu Piso, Michael Ströhlein, Nicola Cerasani, Fabian Kockelmann, Maximilian Schmeding Abstract Background: For carefully selected patients with peritoneal surface malignancies (PSMs), secondary cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) can provide similar oncological results as…
Read MoreCytoreductive surgery and HIPEC for multicystic peritoneal mesothelioma: therapeutic approach in a rare benign neoplasm
Journal of Surgical Case Reports 2026 January 8 [Link] Goran Aleksandrić, Nemanja Trifunović, Jovana Trifunović, Sara Filipović, Nebojša Mitrović Abstract Multicystic peritoneal mesothelioma (MCPM) is an uncommon tumor of mesothelial origin, characterized by multiple interconnected cystic spaces and uncertain biological behavior. Although traditionally considered benign, its tendency to recur and occasionally spread within the peritoneal…
Read MoreExpanding the role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A multicenter study on uncommon peritoneal malignancies
World Journal of Clinical Oncology 2025 December 24 [Link] Massimo Framarini, Fabrizio D’Acapito, Piero Vincenzo Lippolis, Andrea Di Giorgio, Daniela Di Pietrantonio, Antonio Sommariva, Paolo Sammartino Abstract Background: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has become an established treatment for selected patients with peritoneal metastases (PM) from colorectal, ovarian, and gastric cancers,…
Read MoreThe INDEPSO-ISPSM Consensus on Peritoneal Malignancies-Diagnosis and Management of Peritoneal Mesothelioma
Indian Journal of Surgical Oncology 2025 December [Link] Ambarish Chatterjee, Ashwin K Rajagopal, Vivekanand Sharma, Niharika Garach, Ninad Katdare, Rohit Kumar, Swapnil Patel, Mukurdipi Ray, Somashekhar Sp, Sanket Mehta, Vivek Sukumar, Aditi Bhatt Abstract We report the results of a consensus exercise covering the basics of management of peritoneal mesothelioma (PeM) (diagnostic evaluation, patient selection…
Read MoreCo-occurrence of peritoneal mesothelioma and genitourinary cancers: a case series with comparative outcomes
Pleura and Peritoneum 2025 November 3 [Link] Emma M Bradley, James L Rogers, Marissa C Kuo, Deepa Magge Abstract Objectives: Peritoneal mesothelioma (PM) shares features with genitourinary (GU) malignancies, including histologic appearance, embryologic origin and genetic predispositions. However, data on their co-occurrence are limited. The study presents a case series of PM patients with associated…
Read MoreDynamic evolution of NK cells and immune remodeling mediated by CRS + HIPEC: prognostic mechanisms and therapeutic implications for malignant peritoneal mesothelioma
World Journal of Surgical Oncology 2025 November 3 [Link] Yi-Tong Liu, Qi-Di Zhao, Xin-Li Liang, Ru Ma, Yan-Dong Su, Rui Yang, Tian Wei, He-Liang Wu, Yu-Bin Fu, Yu-Run Cui, Yang Yu, Bing Li, Yan Li Abstract Background: Malignant peritoneal mesothelioma (MPM) is a highly aggressive peritoneal malignancy with a significant recurrence rate following cytoreductive surgery…
Read MoreComparison of the Efficacy of First-Line Pemetrexed-Platinum and Gemcitabine-Platinum Regimens in Malignant Peritoneal Mesothelioma
Clinical Medicine Insights Oncology 2025 October 17 [Link] Doğan Bayram, Safa Can Efil, Serap Türk, Oğuz Kara, Serhat Sekmek, Şebnem Yücel, Selin Aktürk Esen, Gökhan Uçar, Oznur Bal, Efnan Algin, Doğan Uncu Abstract Background: Malignant peritoneal mesothelioma (MPeM) is a rare and progressive cancer originating from the mesothelial cells of the peritoneum. In patients with…
Read MoreNeoadjuvant immunotherapy in a solitary, isolated peritoneal mesothelioma involving the abdominal wall: a case report
Immunotherapy 2025 July [Link] Parsa Charkhchi, Ryan Le, Taryn E Cazzolli, Raina R Flores, Roberto A Martinez, Supreet Kaur, Mio Kitano Abstract Mesothelioma is a rare neoplasm with a minority of cases originating from the peritoneum. Patients are generally treated with a combination of cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, and various systemic therapies. In recent…
Read More
Skip to content